Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors
暂无分享,去创建一个
R. Paredes | B. Clotet | J. Prado | M. Massanella | J. Blanco | J. Carrillo | A. Kilpeläinen | L. Mateu | C. Brander | B. Quirant-Sánchez | I. Blanco | D. Ouchi | R. Pérez-Caballero | E. Martínez-Cáceres | O. Blanch-Lombarte | E. Jimenez-Moyano | R. Peña | A. Chamorro | Esther Jimenez-Moyano | Oscar Blanch-Lombarte | Athina Kilpeläinen
[1] A. Sette,et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant , 2022, Nature Medicine.
[2] Wenyu Song,et al. The effectiveness of dextrose prolotherapy in plantar fasciitis , 2021, Medicine.
[3] H. Volk,et al. Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology , 2021, Frontiers in Immunology.
[4] A. Mehta,et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells , 2021, Cell Reports Medicine.
[5] F. Balloux,et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 infection , 2021, medRxiv.
[6] Rahul Singh,et al. Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options , 2021, Biomedicine & Pharmacotherapy.
[7] A. Mehta,et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells , 2021, medRxiv.
[8] S. Kent,et al. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity , 2021, Immunity.
[9] A. Jenkner,et al. Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies , 2021, Cell Reports.
[10] A. Godzik,et al. Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.
[11] V. Gushchin,et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia , 2021, The Lancet.
[12] Nguyen H. Tran,et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials , 2021, The Lancet.
[13] A. Butte,et al. Age- and Sex-Associated Variations in the Sensitivity of Serological Tests Among Individuals Infected With SARS-CoV-2 , 2021, JAMA network open.
[14] R. Paredes,et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes , 2021, Med.
[15] R. Paredes,et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity , 2021, Scientific Reports.
[16] M. Nussenzweig,et al. Persistent cellular immunity to SARS-CoV-2 infection , 2021, The Journal of experimental medicine.
[17] L. McCullough,et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area , 2021, PloS one.
[18] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[19] T. Kirby. New variant of SARS-CoV-2 in UK causes surge of COVID-19 , 2021, The Lancet Respiratory Medicine.
[20] J. Gargano,et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[21] A. Iafrate,et al. COVID-19-neutralizing antibodies predict disease severity and survival , 2020, Cell.
[22] Young Keun Kim,et al. PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19 , 2020, Immunity.
[23] D. Lauffenburger,et al. Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[24] Elisabeth Mahase. Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy , 2020, BMJ.
[25] L. Cuevas,et al. IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection , 2020, Emerging infectious diseases.
[26] L. Carter,et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19 , 2020, Cell.
[27] Sagar,et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells , 2020, Nature Medicine.
[28] F. Heinemann,et al. Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2–Specific IgG , 2020, Emerging infectious diseases.
[29] P. Meybohm,et al. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study , 2020, Frontiers in Immunology.
[30] R. Harrington,et al. The impact of novel coronavirus COVID‐19 on noncommunicable disease patients and health systems: a review , 2020, Journal of internal medicine.
[31] H. Rammensee,et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition , 2020, Nature immunology.
[32] J. Greenbaum,et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.
[33] P. Sopp,et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.
[34] M. Marshall. The lasting misery of coronavirus long-haulers , 2020, Nature.
[35] U. Stervbo,et al. Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients , 2020, Cell Reports Medicine.
[36] S. Farhadian,et al. Sex differences in immune responses that underlie COVID-19 disease outcomes , 2020, Nature.
[37] S. Mallal,et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.
[38] Eric Song,et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.
[39] Sasikanth Manne,et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.
[40] Aaron M. Rosenfeld,et al. Comprehensive mapping of immune perturbations associated with severe COVID-19 , 2020, Science Immunology.
[41] Martin Linster,et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.
[42] Morten Nielsen,et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.
[43] Aaron J. Wilk,et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19 , 2020, Nature Medicine.
[44] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[45] I. Amit,et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.
[46] Li Yang,et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis , 2020, International Journal of Infectious Diseases.
[47] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[48] Yan Liu,et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.
[49] Yong-tang Zheng,et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients , 2020, Cellular & Molecular Immunology.
[50] A. Singh,et al. Delineation of Homeostatic Immune Signatures Defining Viremic Non-progression in HIV-1 Infection , 2020, Frontiers in Immunology.
[51] De-Min Han,et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality , 2020, Frontiers in Public Health.
[52] Lijuan Xiong,et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients , 2020, EBioMedicine.
[53] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[54] B. Clotet,et al. Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab , 2019, Journal of clinical medicine.
[55] D. Kaufmann,et al. Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells , 2017, PloS one.
[56] C. Van Lint,et al. Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation , 2015, Journal of Virology.
[57] B. Korber,et al. Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected. , 2015, The Journal of infectious diseases.
[58] M. Lederman,et al. Limited HIV Infection of Central Memory and Stem Cell Memory CD4+ T Cells Is Associated with Lack of Progression in Viremic Individuals , 2014, PLoS pathogens.
[59] Jack T Stapleton,et al. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation , 2010, Science.
[60] J. Xie,et al. Long-Term Persistence of Robust Antibody and Cytotoxic T Cell Responses in Recovered Patients Infected with SARS Coronavirus , 2006, PloS one.
[61] I. Kang,et al. Age-associated changes in the frequency of naïve, memory and effector CD8+ T cells , 2004, Mechanisms of Ageing and Development.
[62] D. Zenkert,et al. a review , 2019 .
[63] David Heckerman,et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load , 2007, Nature Medicine.